Bristol-Myers Squibb Co(BMY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 14.19 | EPS (ttm) | 4.54 | Insider Own | 0.32% | Shs Outstand | 2.04B | Perf Week | -3.75% |
| Market Cap | 131.57B | Forward P/E | 9.83 | EPS next Y | -5.43% | Insider Trans | -0.46% | Shs Float | 2.04B | Perf Month | -0.66% |
| Enterprise Value | 165.56B | PEG | - | EPS next Q | 1.72 | Inst Own | 85.13% | Short Float | 2.25% | Perf Quarter | 14.04% |
| Income | 9.28B | P/S | 2.67 | EPS this Y | 12.67% | Inst Trans | 0.85% | Short Ratio | 4.04 | Perf Half Y | 7.12% |
| Sales | 49.20B | P/B | 5.9 | EPS next 5Y | -2.89% | ROA | 10.18% | Short Interest | 45.85M | Perf YTD | 19.41% |
| Book/sh | 10.92 | P/C | 11.89 | EPS past 3/5Y | 5.47% - | ROE | 46.7% | 52W High | -6.16% ($68.64) | Perf Year | 36.38% |
| Cash/sh | 5.42 | P/FCF | 11.5 | Sales past 3/5Y | 1.45% 2.54% | ROIC | 14.03% | 52W Low | 51.48% ($42.52) | Perf 3Y | 5.9% |
| Dividend Est. | $2.34 (3.63%) | EV/EBITDA | 8.62 | EPS Y/Y TTM | 83.17% | Gross Margin | 66.64% | Volatility(W/M) | 2.01% 2.05% | Perf 5Y | 1.31% |
| Dividend TTM | 2.51 | EV/Sales | 3.37 | Sales Y/Y TTM | 3.13% | Oper. Margin | 32.35% | ATR (14) | 1.52 | Perf 10Y | 15.72% |
| Dividend Ex-Date | 2026/7/2 | Quick Ratio | 1.38 | EPS Q/Q | 49.96% | Profit Margin | 18.87% | RSI (14) | 45.44 | Recom | 2.45 |
| Dividend Gr. 3/5Y | 4.37% 6.24% | Current Ratio | 1.53 | Sales Q/Q | 6.22% | SMA20 | -2.75% ($66.23) | Beta | 0.18 | Target Price | $66.04 |
| Payout | 71.98% | Debt/Eq | 2.02 | Earnings | 2026/7/30 | SMA50 | 1.98% ($63.16) | Rel Volume | 0.56 | Prev Close | $64.69 |
| Employees | 32500 | LT Debt/Eq | 1.96 | EPS/Sales Surpr. | 27.73% 10.51% | SMA200 | 10.44% ($58.32) | Avg Volume(3M) | 11.35M | Price | $64.41 |
| IPO | 1929/7/5 | Option/Short | Yes/Yes | Trades | 40944 | Volume | 6,403,951 | Change | -0.43% |
Company
BMY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A global large-cap pharmaceutical company with a broad new drug portfolio spanning oncology, immunology, cardiovascular, and hematology disease areas. The company in its current form was established through the 1989 merger of Bristol Myers and Squibb, is headquartered in New Jersey, and operates key blockbuster new drugs in the oncology and immunology fields.
Over the past 1 year, on the higher side
6% below its 1-year high.
BMY makes money exceptionally well
32.35% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +12.7% this year.
Tap to view numbers
The price looks about right
Trading at 14.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +5.9% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.63% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 85.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
OWN 0.07%
FTXH 0.06%
ROPE 0.05%
MFVL 0.05%
RDIV 0.05%It ranks #4 in the industry
Based on market cap of $132B.
BMY $132B PER 14.2
LLY $1.1T PER 38.2
JNJ $644B PER 31.0
ABBV $443B PER 70.9
실적분석 · 7/30 Bristol-Myers Squibb ($BMY) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Beat by Wide Margins, Full-Year Guidance Raised 투자 가이드 · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats 투자 가이드 · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is BMY?
BMY belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of BMY?
The market cap of BMY is approximately $131.6B, ranking 119 within its sector.
Does BMY pay dividends?
BMY has a dividend yield of approximately 3.63%, with an annual dividend of $2.34.
What is the P/E ratio of BMY?
BMY has a P/E ratio of approximately 14.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BMY?
BMY has recorded a 52-week high of $68.64 and a low of $42.52.
